FloLipid Withdrawal: FDA Moves to Pull the First US Liquid Statin Over Missing Annual Reports

FloLipid withdrawal FDA liquid statin infographic

The FloLipid withdrawal process is under way: the US Food and Drug Administration has proposed to withdraw approval of FloLipid, Salerno Pharmaceuticals’ simvastatin oral suspension marketed as the first liquid statin in the United States, because the company repeatedly failed to file required annual reports. The notice, published in the Federal Register on 18 November 2026 (document 2026-23413, docket FDA-2026-N-9703), gives the Tulsa, Oklahoma company until 18 December 2026 to request a hearing.

Key takeaways on the FloLipid withdrawal

  • FDA’s drug center proposes to withdraw NDA 206679 for FloLipid suspension, 20 mg/5 mL and 40 mg/5 mL.
  • The stated basis is repeated failure to submit annual reports, not a newly announced safety or efficacy finding.
  • According to Reuters, Salerno also did not respond when FDA asked for the missing reports.
  • Salerno can request a hearing by 18 December 2026; supporting data and public comments are due by 19 January 2027.
  • Simvastatin itself remains widely available as generic tablets, and other liquid cholesterol options exist.

What FloLipid is and who uses it

FloLipid was approved in April 2016 as an oral suspension of simvastatin, one of the oldest and most prescribed cholesterol-lowering statins. The point of the product was format, not chemistry: a ready-made liquid for people who struggle to swallow tablets, such as some older adults, stroke survivors with dysphagia and patients fed through tubes. Before liquid statins existed, pharmacists often had to crush tablets or compound suspensions themselves, which introduces dose and stability questions.

That niche helps explain why a reporting lapse matters. FloLipid has always been a small product next to the generic tablet market, and a company that stops investing in a low-volume brand can also stop keeping up with its regulatory paperwork.

Why missing annual reports can end an approval

Approval of a new drug application is not a one-time event. Under FDA regulations (21 CFR 314.81), every NDA holder must submit an annual report each year on the anniversary of approval. It summarises new safety and clinical information, distribution data, labeling changes and chemistry, manufacturing and controls (CMC) updates. These reports are one of the main ways FDA keeps track of how an approved product is being made and what has changed since approval.

Section 505(e) of the Federal Food, Drug, and Cosmetic Act allows FDA to withdraw an approval when a sponsor fails to make required reports, after notice and an opportunity for a hearing. FDA uses this tool sparingly and usually after repeated requests go unanswered. That appears to be the pattern here: according to Reuters, the agency asked Salerno to submit the reports and received no response.

FloLipid withdrawal timeline

DateEvent
April 2016FDA approves FloLipid (simvastatin oral suspension), NDA 206679
17 Nov 2026Notice placed on public inspection; Reuters reports the proposal
18 Nov 2026Notice published in the Federal Register (2026-23413)
18 Dec 2026Deadline for Salerno to request a hearing
19 Jan 2027Deadline for data and analyses supporting a hearing, and for public comments
Source: Federal Register notice, docket FDA-2026-N-9703; Reuters; Becker’s Hospital Review.

If Salerno does not request a hearing in time, the company is generally treated as having waived it, and FDA can finalise the withdrawal with a later notice. If it does request one, it has to show a genuine factual dispute, for example that the reports were filed or that the lapse has been cured.

What patients and pharmacists should know

Nothing in the published summaries points to a new safety problem with simvastatin or with FloLipid itself; the action is about regulatory compliance. People taking FloLipid should not stop their cholesterol treatment on their own, since stopping a statin can raise cardiovascular risk. The sensible step is to ask a doctor or pharmacist about an alternative before supply becomes an issue.

  • Generic simvastatin tablets remain widely available for patients who can swallow them.
  • Other liquid statins exist, including atorvastatin oral suspension (Atorvaliq), approved in 2023.
  • Pharmacy compounding remains an option for patients with special needs, at the prescriber’s discretion.

The bigger signal for drugmakers

The FloLipid case is a reminder that post-approval obligations outlive commercial interest. Small specialty companies that acquire or launch niche reformulations sometimes treat them as low-maintenance assets, yet annual reports, adverse event reporting and CMC change filings apply in full no matter how few units are sold. FDA has used the same withdrawal route against other dormant or non-reporting applications in recent years, and the agency’s enforcement posture has tightened across manufacturing and compliance. Recent examples on this site include a 45-state generic price-fixing settlement and FDA’s move to settle the status of NAC as a dietary supplement. More news in our Pharmaceuticals section.

Market context

Losing one brand will not dent a large and largely generic category. Acumen Research and Consulting’s cholesterol lowering drugs market report projected the market to grow at a CAGR of around 7.1% from 2020 to 2027, reaching about US$27.5 billion by 2027, with retail pharmacies the leading distribution channel. The report was last updated in December 2020, so these figures are indicative. Growth in the category has come mainly from newer non-statin therapies, while statins compete largely on price, which is part of why a niche branded liquid simvastatin had limited commercial weight.

FAQ

Why is FDA withdrawing FloLipid?

FDA says Salerno Pharmaceuticals repeatedly failed to file the annual reports required for every approved new drug application. The proposal is based on that reporting failure.

Is FloLipid unsafe?

The published notice summaries do not cite a new safety finding. Patients with questions should speak to their doctor or pharmacist rather than stopping treatment.

Is there another liquid statin?

Yes. Atorvastatin is available as an oral suspension, and pharmacists can compound liquid forms when needed. A prescriber can advise which option fits.

When will FloLipid be removed?

Not immediately. Salerno has until 18 December 2026 to request a hearing. FDA would need to publish a final withdrawal notice before the approval ends.

Sources: Federal Register notice 2026-23413; Reuters (17 November 2026); Becker’s Hospital Review. Market data: Acumen Research and Consulting. Not medical or investment advice. Last updated 19 November 2026.

Leave a Reply

Your email address will not be published. Required fields are marked *